By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Bruker on Wednesday with an Outperform rating and a Core Growth company profile.

Analyst Amanda Murphy estimated 2011 EPS at $.89 on $1.63 billion in revenues, and 2012 EPS at $1.05 on $1.77 billion in revenues.

In a research note, Murphy cited Bruker's spending on R&D, which she said is higher than its peers on a percentage-of-revenue basis, resulting in strong brand reputation and a "robust" IP portfolio.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.